ʟ-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
| Autor: | Tomoyuki Mine, Kenji Nagao, Masamichi Takeshita, Yasuyo Suga, Yasuo Kobuna, Takada Michihiro, Katsuya Suzuki, Ikuko Sasahara, Akiko Yamamoto, Masaki Hashimoto, Natsumi Nishikata |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Knee Joint Brief Pain Inventory (BPI) Placebo-controlled study Medicine (miscellaneous) Osteoarthritis Placebo clinical AcademicSubjects/MED00060 Double-Blind Method Japan Low Back Pain Evaluation Questionnaire (JLEQ) Serine Humans Medicine multiple site pain Brief Pain Inventory neuropathic pain Nutrition and Dietetics business.industry Middle Aged medicine.disease Low back pain Clinical trial Knee pain Eicosapentaenoic Acid Back Pain Neuropathic pain Physical therapy AcademicSubjects/SCI00960 Female Nutrient Physiology Metabolism and Nutrient-Nutrient Interactions Chronic Pain Japanese Knee Osteoarthritis Measure (JKOM) medicine.symptom business low-back and knee pain |
| Zdroj: | The Journal of Nutrition |
| ISSN: | 0022-3166 |
| DOI: | 10.1093/jn/nxaa156 |
| Popis: | Background Multisite pain, including low-back and knee pain, is a major health issue that greatly decreases quality of life. Objectives This study analyzed the effects of l-serine, which provides necessary components for nerve function, and EPA, which exerts anti-inflammatory properties, on pain scores of adults with pain in at least the low back and knee for ≥3 mo. Methods This was a randomized, double-blind, placebo-controlled, parallel-group study. The Japan Low Back Pain Evaluation Questionnaire (JLEQ) and Japanese Knee Osteoarthritis Measure (JKOM) were applied as primary outcomes. The Brief Pain Inventory (BPI) and safety evaluation were secondary outcomes. We enrolled 120 participants aged ≥20 y (36 men and 84 women: mean ± SD age = 40.8 ± 10.9 y). The participants were randomly allocated to either the active group (daily ingestion of 594 mg l-serine and 149 mg EPA) or placebo group. The study period consisted of 8-wk dosing and 4-wk posttreatment observation. ANCOVA between groups for each time point was conducted using the baseline scores as covariates. Results The JLEQ scores (active compared with placebo: 14.2 ± 11.2 compared with 19.0 ± 10.2) at week 8 were lower in the active group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|